Q-RETIX AI
AI-Powered Pharmaceutical Intelligence for Research, Drug Discovery, and Clinical Analysis.
Platform Solutions
Comprehensive AI tools designed for every stage of pharmaceutical research and development.
Smart Drug Discovery
AI-driven molecular screening and target identification to accelerate candidate selection.
AI Data Processing
Real-time processing of multi-omics datasets, clinical records, and research literature.
Clinical Research Intelligence
Automated trial monitoring, patient stratification, and endpoint analysis.
Laboratory Automation
Smart workflow orchestration for high-throughput screening and assay management.
Predictive Healthcare
Machine learning models for outcome prediction, risk stratification, and biomarker discovery.
Research Analytics
Comprehensive dashboards and reports for research progress, compliance, and funding metrics.
Research Timeline
From discovery to delivery — track every milestone with precision and transparency. Our structured pipeline ensures rigorous validation at every stage.
Discovery
Preclinical
Clinical Trials
Regulatory
Manufacturing
Commercial
Latest Insights & Research
Stay updated with breakthroughs in AI-powered healthcare, structural drug discovery, and immunology research.
Trusted by Researchers & Drug Discovery Teams
Hear from pharmaceutical scientists and biotech leaders using Q-RETIX structural AI.
Structural Biology Team Lead
Computational Chemistry Director • European Pharma Consortium
“Q-RETIX's structural AI identified a cryptic pocket our crystallography team missed for two years. The allosteric hinge approach changed how we think about 'undruggable' inflammasomes entirely.”
Immunology Research Head
Principal Investigator • Autoimmune Research Institute
“The electrostatic charge trap stalled our AIM2 program for 18 months. Q-RETIX bypassed it completely by mapping dynamic conformations—something traditional docking could never achieve.”
Drug Discovery VP
VP of Discovery Biology • Clinical-stage Biotech
“We went from target validation to a first-in-class allosteric molecular wedge in 14 weeks. Q-RETIX's AI matrix doesn't just screen compounds—it engineers mechanisms.”
CRO Partnership Director
Strategic Alliance Lead • Global CRO Network
“Our clients demand specificity. Q-RETIX delivered an AIM2 inhibitor with zero cGAS cross-reactivity—a level of selectivity we have never seen from an AI platform.”
Structural Biology Team Lead
Computational Chemistry Director • European Pharma Consortium
“Q-RETIX's structural AI identified a cryptic pocket our crystallography team missed for two years. The allosteric hinge approach changed how we think about 'undruggable' inflammasomes entirely.”
Immunology Research Head
Principal Investigator • Autoimmune Research Institute
“The electrostatic charge trap stalled our AIM2 program for 18 months. Q-RETIX bypassed it completely by mapping dynamic conformations—something traditional docking could never achieve.”
Drug Discovery VP
VP of Discovery Biology • Clinical-stage Biotech
“We went from target validation to a first-in-class allosteric molecular wedge in 14 weeks. Q-RETIX's AI matrix doesn't just screen compounds—it engineers mechanisms.”
CRO Partnership Director
Strategic Alliance Lead • Global CRO Network
“Our clients demand specificity. Q-RETIX delivered an AIM2 inhibitor with zero cGAS cross-reactivity—a level of selectivity we have never seen from an AI platform.”
Translational Medicine Lead
Head of Translational Science • University Medical Center
“The membrane permeability profile was validated in our cellular assays within days. An uncharged, lipophilic AIM2 modulator is exactly what the autoimmune field has been waiting for.”
Biotech Founder
CEO & Co-Founder • Inflammasome Therapeutics
“We evaluated every AI drug discovery platform on the market. Q-RETIX is the only one that found a druggable site on AIM2. That first-mover advantage is now our entire Series A thesis.”
Regulatory Strategy Officer
Chief Regulatory Officer • Mid-size Pharma
“The mechanistic clarity of an allosteric hinge stabilizer makes regulatory conversations straightforward. We have a clear target engagement biomarker and a clean toxicity profile.”
AI Research Scientist
Senior ML Engineer • Structural Genomics Consortium
“As someone who builds protein models, I was skeptical. But Q-RETIX's dynamic ensemble approach finds transient pockets that static AlphaFold structures completely miss.”
Translational Medicine Lead
Head of Translational Science • University Medical Center
“The membrane permeability profile was validated in our cellular assays within days. An uncharged, lipophilic AIM2 modulator is exactly what the autoimmune field has been waiting for.”
Biotech Founder
CEO & Co-Founder • Inflammasome Therapeutics
“We evaluated every AI drug discovery platform on the market. Q-RETIX is the only one that found a druggable site on AIM2. That first-mover advantage is now our entire Series A thesis.”
Regulatory Strategy Officer
Chief Regulatory Officer • Mid-size Pharma
“The mechanistic clarity of an allosteric hinge stabilizer makes regulatory conversations straightforward. We have a clear target engagement biomarker and a clean toxicity profile.”
AI Research Scientist
Senior ML Engineer • Structural Genomics Consortium
“As someone who builds protein models, I was skeptical. But Q-RETIX's dynamic ensemble approach finds transient pockets that static AlphaFold structures completely miss.”
Join The Q-RETIX AI Community
Get early access to pharmaceutical intelligence tools and connect with researchers, scientists, and healthcare innovators worldwide.
Why join?
Connect with pharmaceutical researchers, scientists, healthcare professionals, and AI innovators shaping the future of drug discovery and clinical research.
Newsletter Perks
- Research Articles & Whitepapers
- AI & Machine Learning Insights
- Industry & Regulatory Reports
- Clinical Research Updates
- Drug Discovery Breakthroughs